Cargando…

PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols

SIMPLE SUMMARY: The introduction of therapies with immune checkpoint inhibitors targeting the programmed cell death protein 1 and its ligand (PD-L1) axis in head and neck squamous cell carcinoma prompted the need of reliable bio-selectors to stratify patients that would benefit from these treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: Crosta, Simona, Boldorini, Renzo, Bono, Francesca, Brambilla, Virginia, Dainese, Emanuele, Fusco, Nicola, Gianatti, Andrea, L’Imperio, Vincenzo, Morbini, Patrizia, Pagni, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830149/
https://www.ncbi.nlm.nih.gov/pubmed/33466794
http://dx.doi.org/10.3390/cancers13020292
_version_ 1783641340992552960
author Crosta, Simona
Boldorini, Renzo
Bono, Francesca
Brambilla, Virginia
Dainese, Emanuele
Fusco, Nicola
Gianatti, Andrea
L’Imperio, Vincenzo
Morbini, Patrizia
Pagni, Fabio
author_facet Crosta, Simona
Boldorini, Renzo
Bono, Francesca
Brambilla, Virginia
Dainese, Emanuele
Fusco, Nicola
Gianatti, Andrea
L’Imperio, Vincenzo
Morbini, Patrizia
Pagni, Fabio
author_sort Crosta, Simona
collection PubMed
description SIMPLE SUMMARY: The introduction of therapies with immune checkpoint inhibitors targeting the programmed cell death protein 1 and its ligand (PD-L1) axis in head and neck squamous cell carcinoma prompted the need of reliable bio-selectors to stratify patients that would benefit from these treatments. The assessment of PD-L1 expression through immunohistochemistry represents the most widely used method to perform this task, being recently approved by regulatory authorities. However, borrowing from previous experiences in lung cancer, the heterogeneity of antibodies and platforms used in the routine clinical practice requires a strict multi-institutional harmonization effort. In this setting, the present study is aimed to assess the performances of different PD-L1 staining protocols and the inter-observer reliability for its interpretation. ABSTRACT: Immune checkpoint inhibitors for blocking the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis are now available for squamous cell carcinoma of the head and neck (HNSCC) in relapsing and/or metastatic settings. In this work, we compared the resulting combined positive score (CPS) of PD-L1 using alternative methods adopted in routine clinical practice and determined the level of diagnostic agreement and inter-observer reliability in this setting. The study applied 5 different protocols on 40 tissue microarrays from HNSCC. The error rate of the individual protocols ranged from a minimum of 7% to a maximum of 21%, the sensitivity from 79% to 96%, and the specificity from 50% to 100%. In the intermediate group (1 ≤ CPS < 20), the majority of errors consisted of an underestimation of PD-L1 expression. In strong expressors, 5 out of 14 samples (36%) were correctly evaluated by all the protocols, but no protocol was able to correctly identify all the “strong expressors”. The overall inter-observer agreement in PD-L1 CPS reached 87%. The inter-observer reliability was moderate, with an ICC of 0.774 (95% CI (0.651; 0.871)). In conclusion, our study showed moderate interobserver reliability among different protocols. In order to improve the performances, adequate specific training to evaluate PD-L1 by CPS in the HNSCC setting should be coordinated.
format Online
Article
Text
id pubmed-7830149
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78301492021-01-26 PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols Crosta, Simona Boldorini, Renzo Bono, Francesca Brambilla, Virginia Dainese, Emanuele Fusco, Nicola Gianatti, Andrea L’Imperio, Vincenzo Morbini, Patrizia Pagni, Fabio Cancers (Basel) Article SIMPLE SUMMARY: The introduction of therapies with immune checkpoint inhibitors targeting the programmed cell death protein 1 and its ligand (PD-L1) axis in head and neck squamous cell carcinoma prompted the need of reliable bio-selectors to stratify patients that would benefit from these treatments. The assessment of PD-L1 expression through immunohistochemistry represents the most widely used method to perform this task, being recently approved by regulatory authorities. However, borrowing from previous experiences in lung cancer, the heterogeneity of antibodies and platforms used in the routine clinical practice requires a strict multi-institutional harmonization effort. In this setting, the present study is aimed to assess the performances of different PD-L1 staining protocols and the inter-observer reliability for its interpretation. ABSTRACT: Immune checkpoint inhibitors for blocking the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis are now available for squamous cell carcinoma of the head and neck (HNSCC) in relapsing and/or metastatic settings. In this work, we compared the resulting combined positive score (CPS) of PD-L1 using alternative methods adopted in routine clinical practice and determined the level of diagnostic agreement and inter-observer reliability in this setting. The study applied 5 different protocols on 40 tissue microarrays from HNSCC. The error rate of the individual protocols ranged from a minimum of 7% to a maximum of 21%, the sensitivity from 79% to 96%, and the specificity from 50% to 100%. In the intermediate group (1 ≤ CPS < 20), the majority of errors consisted of an underestimation of PD-L1 expression. In strong expressors, 5 out of 14 samples (36%) were correctly evaluated by all the protocols, but no protocol was able to correctly identify all the “strong expressors”. The overall inter-observer agreement in PD-L1 CPS reached 87%. The inter-observer reliability was moderate, with an ICC of 0.774 (95% CI (0.651; 0.871)). In conclusion, our study showed moderate interobserver reliability among different protocols. In order to improve the performances, adequate specific training to evaluate PD-L1 by CPS in the HNSCC setting should be coordinated. MDPI 2021-01-14 /pmc/articles/PMC7830149/ /pubmed/33466794 http://dx.doi.org/10.3390/cancers13020292 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Crosta, Simona
Boldorini, Renzo
Bono, Francesca
Brambilla, Virginia
Dainese, Emanuele
Fusco, Nicola
Gianatti, Andrea
L’Imperio, Vincenzo
Morbini, Patrizia
Pagni, Fabio
PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
title PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
title_full PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
title_fullStr PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
title_full_unstemmed PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
title_short PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
title_sort pd-l1 testing and squamous cell carcinoma of the head and neck: a multicenter study on the diagnostic reproducibility of different protocols
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830149/
https://www.ncbi.nlm.nih.gov/pubmed/33466794
http://dx.doi.org/10.3390/cancers13020292
work_keys_str_mv AT crostasimona pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols
AT boldorinirenzo pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols
AT bonofrancesca pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols
AT brambillavirginia pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols
AT daineseemanuele pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols
AT fusconicola pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols
AT gianattiandrea pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols
AT limperiovincenzo pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols
AT morbinipatrizia pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols
AT pagnifabio pdl1testingandsquamouscellcarcinomaoftheheadandneckamulticenterstudyonthediagnosticreproducibilityofdifferentprotocols